Targeting syndecan-2 inhibits papillary thyroid cancer invasiveness and de-differentiation
Our findings suggest that SDC2 would be a promising therapy target for advanced radioiodine refractory thyroid cancer, but the role in PTC progression is complicated and requires further exploration.
Authors
- Lianhong Zou (ORCID: https://orcid.org/0000-0002-0964-7447)
- Xin Lv (ORCID: https://orcid.org/0000-0002-3352-7162)
- Zhen Cao (ORCID: https://orcid.org/0000-0003-3369-5526)
- Yuqing Zhang (ORCID: https://orcid.org/0000-0002-9354-655X)
- Rui Liu (ORCID: https://orcid.org/0000-0001-7573-3346)
- Huiling Wang (ORCID: https://orcid.org/0000-0001-5565-7163)
- Ziwen Liu (ORCID: https://orcid.org/0000-0003-1574-8460)
- Chaojie Zhang (ORCID: https://orcid.org/0000-0003-3108-8271)
Institutions
- Hunan Normal University (CN)
- Chinese Academy of Medical Sciences & Peking Union Medical College (CN)
- Peking Union Medical College Hospital (CN)
- Hunan Provincial People's Hospital (CN)
Publication Details
- Journal
- BMC Endocrine Disorders
- Published
- 2025-10-28
- DOI
- https://doi.org/10.1186/s12902-025-02055-3
- Primary Topic
- Proteoglycans and glycosaminoglycans research
- Type
- article
- Field-Weighted Citation Impact
- 0.00